Imunon agrees to sell ThermoDox rights to VoxelDox Therapeutics
The October 20, 2026 deal gives Imunon equity, milestone payments up to $16.5 million, and royalties, while it keeps focus on its Phase 3 OVATION 3 trial.
SEC filing (5)
Latest
Wednesday, October 21
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC data
Arcus proposed a common stock offering through underwriters Jefferies, Leerink Partners and TD Cowen, pointing to casdatifan results and an estimated $694.0 million cash balance.
SEC filing (3)
Neogen raises fiscal 2027 revenue, EBITDA outlook on first-quarter growth
Neogen lifted full-year guidance after first-quarter core revenue grew 8.1% and said Petrifilm manufacturing and a pending Zoetis divestiture remain on schedule.
SEC filing (11)
Roivant and Priovant report positive Phase 3 results for brepocitinib in uveitis
Both CLARITY-1 and CLARITY-2 trials hit their primary and key secondary endpoints, with an sNDA filing planned for the first half of 2027.
SEC filing
Alpha Teknova launches common stock offering, discloses preliminary Q3 2026 results
The Hollister, California reagents maker filed a preliminary prospectus supplement dated October 20, 2026 for an undetermined number of shares, alongside early third-quarter revenue and margin estimates.
SEC filing (3)
BeOne Medicines registers Phase 1 trial of BG-T0050 in DLBCL and other B-cell cancers
Voyager Therapeutics names Robin Swartz president, sets up CEO transition
Voyager's board elevated Swartz to president effective October 20, 2026, with plans for her to become CEO after early safety data from a VY1706 Alzheimer's trial arrive.
SEC filing
HUTCHMED closes HMPL-A830 license deal with GSK for territories outside China
The licensing agreement covering the KRAS-EGFR antibody conjugate candidate took effect after antitrust clearance, triggering a $110 million upfront payment.
SEC filing
Supernus gets orphan exclusivity for ONAPGO, files sNDA for second supplier
FDA recognized seven years of orphan-drug exclusivity for ONAPGO starting February 3, 2025, as Supernus seeks a second manufacturing supplier with potential approval by mid-2027.
SEC filing (2)
Model Medicines files Form D for $8 million offering
The San Diego-based company has sold $5.1 million of the equity offering to 37 investors so far, according to an SEC filing.
SEC filing
Disc Medicine prices offering at 6 million shares, raising about $450 million
Disc Medicine finalized terms for its stock offering, pricing 6,000,000 shares at $75.00 each, after reporting positive Phase 3 APOLLO results for bitopertin.
SEC filing (3)
Nanoviricides updates at-the-market offering cap to $2.37 million
Tiziana to join ACTRIMS-ECTRIMS meeting in Toronto on foralumab programs
Tuesday, October 20
Optimi completes MDMA batch for Canada trial, Israel study, Australia supply
The Vancouver company said a single production run will support a proposed Canadian Phase 3 PTSD trial, a MAPS-partnered study in Israel, and continued commercial exports to Australia.
SEC filing
Odyssey reports completed Phase 2a OD-001 induction data at UEG Week 2026
The company said RIPK2 inhibitor OD-001 hit its primary endpoint in ulcerative colitis, with biomarker and transcriptomic data backing a 20 mg twice-daily dose ahead of planned Phase 2b and Phase 2a combination studies.
SEC filing
FDA approves first generic of Climara Pro hormone therapy patch
The agency cleared Zydus Pharmaceuticals' generic estradiol and levonorgestrel transdermal system, a once-weekly menopause patch for women with an intact uterus.
FDA press release, FDA, Drugs@FDA (3)
FDA approves pralsetinib for RET fusion-positive non-small cell lung cancer
The agency's approval announcement covers pralsetinib for patients with RET gene fusion-positive non-small cell lung cancer.
FDA
Incyte terminates two Phase 2 trials of INCB099280
Both studies were stopped for strategic business reasons with no safety concerns cited, according to the trial registry records.
ClinicalTrials.gov (2)
FDA approves GSK's Hibsago for chronic hepatitis B
The antisense oligonucleotide, given with existing antiviral therapy, lets some adults stop all HBV treatment and keep the virus under control.
SEC filing, Drugs@FDA, FDA, FDA press release (6)
Lakefront Biotherapeutics completes buyback program, holdings reach 1,985,157 shares
A final weekly repurchase of 107,804 shares between October 12 and 16, 2026 completed the June 9, 2026 program, lifting Lakefront's own-share holding to 1,985,157.
SEC filing (11)
Pluri completes $1.25 million share and warrant sale to chairman-linked holder
Pluri Inc. finalized a securities purchase agreement with Chutzpah Holdings LP, converting a prior advance payment into shares and warrants priced at $1.50 and $1.65.
SEC filing
Surrozen closes $95.1 million second tranche after FDA IND clearance for SZN-8141
The financing, triggered by FDA clearance of the SZN-8141 IND, gives Surrozen cash runway into 2029 to run the DUET Phase 1b/2a study and start SZN-8143 development.
SEC filing
Phase II NEO-MEL-T melanoma trial posts results after reaching primary completion
Myriad Genetics to sell prenatal testing unit to Labcorp for $210 million
The companies signed a definitive agreement on October 19, 2026, with the deal expected to close by early 2027 pending regulatory clearance.
SEC filing
Nuvation Bio registers Phase 2 trial of safusidenib for IDH1-mutant glioma after vorasidenib failure
Vertex adds Daniel Brennan to board, expands to eleven directors
Vertex named the former Boston Scientific CFO to its board on October 20, 2026, with a $400,000 restricted stock unit award vesting in 2027.
SEC filing
Scinai says new CDMO deal and financing extend runway toward 2027-2028
The CEO told shareholders a CDMO agreement and $5.3 million in combined financing proceeds support an operating runway to late 2027, possibly stretching to Q3 2028.
SEC filing (3)
Insmed adds Paul Hudson and Utpal Koppikar to board of directors
Former Sanofi CEO Hudson and Verily Health CFO Koppikar join as independent directors effective October 19, 2026, with board committee assignments and equity grants detailed in the filing.
SEC filing
Inhibikase names Kailera CMO Scott Wasserman to board, Berman resigns
The PAH drug developer added a cardiologist with Amgen and Kailera ties to its board as it advances a Phase 3 trial of IKT-001.
SEC filing
Indaptus Therapeutics closes $24.0 million private placement
The company issued 20,338,974 shares to purchasers after a deadline extension pushed the closing date to October 16, 2026.
SEC filing
Crosslink Therapeutics files Form D for $5.5 million offering
The Boston-based pharmaceutical company reported selling all of a $5.5 million offering to eight investors under a Rule 506(b) exemption.
SEC filing
First Tracks Biotherapeutics closes $200 million private placement
The San Diego biotech completed its previously announced stock sale on October 19, 2026 and signed a registration rights agreement with investors.
SEC filing (2)
Janssen posts UNIFI Jr Phase 3 pediatric ulcerative colitis results for ustekinumab
Lifecore Biomedical sets November 4 record date for merger vote
Monday, October 19
FDA grants accelerated approval to dostarlimab for rectal cancer
The agency cleared Jemperli for a new use in locally advanced rectal cancer, saying it may let some patients skip chemotherapy, radiation, and surgery.
FDA, FDA press release, Drugs@FDA, SEC filing (5)
KU Leuven registers interventional Aveir leadless pacemaker study; not yet recruiting
BrainsWay announces collaboration with Inland Psychiatric Medical Group in Southern California
BrainsWay said the partnership includes a multisystem order of its Deep TMS devices for installation at IPMG clinics, with joint research projects also planned.
SEC filing
CytoDyn names Robert Hoffman CEO, moves Lalezari to research role
CytoDyn said Robert E. Hoffman becomes CEO effective October 20, 2026, as Jacob Lalezari shifts to lead research on leronlimab in solid-tumor oncology.
SEC filing
Scienture reports preliminary Q3 2026 revenue of $1.22 million, up sharply on Rezenopy launch
The company's second FDA-approved product, Rezenopy nasal spray, began commercial shipments in August 2026, lifting preliminary quarterly revenue alongside continued Arbli growth.
SEC filing
CRISPR Therapeutics names Andrew Silver CFO, Raju Prasad resigns
Silver, promoted from SVP Finance, becomes CFO effective immediately on October 19, 2026, as Prasad departs for outside opportunities.
SEC filing
Adela, Inc. files Form D for $12 million convertible note offering
The Foster City biotechnology company reported selling the full $12 million offering to five investors, with notes convertible into equity.
SEC filing
Change Agents Corporation issues warrants and promissory notes in October 2026 financings
The company obtained prepayment waivers from two lenders by issuing pre-funded warrants and separately took on two short-term unsecured notes due December 1, 2026.
SEC filing
Novo Nordisk registers real-world semaglutide study with Eucalyptus in Australia
Mineralys Therapeutics expands board with two new directors
Kristine Peterson and Lonnel Coats join the board effective October 19, 2026, growing the body to nine members.
SEC filing
Tempest Therapeutics appoints John W. Frederick to board of directors
The clinical-stage CAR-T company named the former Skillsoft CFO as a Class III director effective October 13, 2026.
SEC filing
Curanex faces two securities class actions tied to 2025 IPO
Both lawsuits, filed in New York state court, allege misstatements in Curanex's IPO offering documents about stock-manipulation risks and underwriter compliance.
SEC filing
Clene secures fourth-year NIH subaward with NYU for ALS program
Clene Inc. disclosed a new funding amendment tied to its long-running NIH grant supporting expanded access to CNM-Au8 for ALS patients.
SEC filing
Arcus Biosciences' ARC-10 lung cancer trial listed as completed as of Oct 2026 update
Collegium and Grünenthal settle Nucynta patent litigation
Collegium Pharmaceutical agreed to pay Grünenthal GmbH $17 million to end a patent suit and terminate their license tied to the Nucynta products.
SEC filing
iBio stockholders approve share authorization boost and incentive plan change
At its October 14, 2026 annual meeting, iBio investors backed raising authorized common stock and amending the equity incentive plan's evergreen formula.
SEC filing